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Chikungunya virus (CHIKV) is a mosquito-trans-
mitted RNA virus that causes acute febrile infection
associated with polyarthralgia in humans. Mecha-
nisms of protective immunity against CHIKV are
poorly understood, and no effective therapeutics or
vaccines are available. We isolated and character-
ized human monoclonal antibodies (mAbs) that
neutralize CHIKV infectivity. Among the 30 mAbs iso-
lated, 13 had broad and ultrapotent neutralizing
activity (IC50 < 10 ng/ml), and all of these mapped
to domain A of the E2 envelope protein. Potent inhib-
itory mAbs blocked post-attachment steps required
for CHIKV membrane fusion, and several were pro-
tective in a lethal challenge model in immunocom-
promised mice, even when administered at late
time points after infection. These highly protective
mAbs could be considered for prevention or treat-
ment of CHIKV infection, and their epitope location
in domain A of E2 could be targeted for rational struc-
ture-based vaccine development.
INTRODUCTION
Chikungunya virus (CHIKV) is an enveloped, positive-sense RNA
virus in the Alphavirus genus of the Togaviridae family and is
transmitted by Aedes species mosquitoes. The mature CHIKV
virion contains two glycoproteins, the E1 fusion protein and the
E2 attachment protein, which are generated from a precursor
polyprotein, p62-E1, by proteolytic cleavage. In humans, CHIKV86 Cell Host & Microbe 18, 86–95, July 8, 2015 ª2015 Elsevier Inc.infection causes fever and joint pain, which may be severe and
last in some cases for years (Schilte et al., 2013; Sissoko et al.,
2009; Staples et al., 2009). CHIKV has caused outbreaks in
most regions of sub-Saharan Africa and also in parts of Asia, Eu-
rope, and the Indian and Pacific Oceans. In December 2013, the
first transmission of CHIKV in theWestern Hemisphere occurred,
with autochthonous cases identified in St. Martin (CDC, 2013).
The virus spread rapidly to many islands in the Caribbean as
well as Central, South, and North America. In less than 1 year,
over a million suspected CHIKV cases in the Western Hemi-
sphere were reported, and endemic transmission in more than
40 countries, including the United States, was documented
(CDC, 2014). At present, there is no licensed vaccine or antiviral
therapy to prevent or treat CHIKV infection.
Although mechanisms of protective immunity to CHIKV infec-
tion in humans are not fully understood, the humoral response
controls infection and limits tissue injury (Chu et al., 2013; Hallen-
ga¨rd et al., 2014; Hawman et al., 2013; Kam et al., 2012b; Lum
et al., 2013; Pal et al., 2013). Immune human g-globulin neutral-
izes infectivity in cultured cells and prevents morbidity in mice
when administered up to 24 hr after viral inoculation (Couderc
et al., 2009). Several murine monoclonal antibodies (mAbs) that
neutralize CHIKV infection have been described (Bre´hin et al.,
2008; Goh et al., 2013; Masrinoul et al., 2014; Pal et al., 2013,
2014), including some with efficacy when used in combination
to treat mice or nonhuman primates following CHIKV challenge
(Pal et al., 2013, 2014). In comparison, a limited number of hu-
man CHIKVmAbs have been reported, the vast majority of which
exhibit modest neutralizing activity (Fong et al., 2014; Fric et al.,
2013; Lee et al., 2011; Selvarajah et al., 2013;Warter et al., 2011).
We isolateda largepanel of humanmAbs that neutralizeCHIKV
infectivity in cell culture and successfully treated immunodefi-
cient Ifnar/mice (lacking type I interferon receptors) inoculated
with a lethal dose of CHIKV, even when administered as late as
60 hr after infection.We identified theAdomain of E2 as themajor
antigenic site for recognition by human mAbs that broadly
neutralize CHIKV infection with ultrapotent activity and showed
that the principal mechanism of inhibition is to prevent fusion.
RESULTS
Isolation of CHIKV-Specific Human mAbs
We isolated a panel of mAbs from a single individual who ac-
quired CHIKV infection in Sri Lanka in 2006 and presented with
fever, arthralgias, and rash (Figure S1). We transformed B cells
in two separate experiments from a single blood sample
collected from the donor five and a half years following natural
infection. We observed a virus-specific B cell frequency of
0.1% of total B cells and established 30 stable hybridomas
from B cell lines secreting antibodies that bound to virus.
The mAb panel contained IgGs of multiple subclasses, with
24 IgG1, 3 IgG2, and 2 IgG3; one was not determined due to
poor hybridoma growth (Table 1). We determined the nucleotide
sequences of the antibody variable gene region using cDNA of
expressed antibody mRNAs in the cloned hybridomas. Each of
the clones used distinct sequences to encode the associated
mAbs, except for mAbs 2B4 and 4J21, which appeared identical
in the variable regions and exhibited similar functional activity.
Assessment of mAb Neutralization with SL15649 VRPs
Seventeen of the mAbs exhibited neutralizing activity against
ECSA CHIKV strain SL15649-GFP virus replicon particles (VRPs)
with EC50 values< 40ng/ml,with 7 exhibitingultrapotent inhibitory
activity (defined as EC50 values < 10 ng/ml, Table 1). Five mAbs
possessed weak inhibitory activity (EC50 values in the 0.095 to
5.2 mg/ml range) and 8 of the mAbs had no inhibitory activity at
the highest concentration tested (EC50 values > 10 mg/ml).
Breadth of Neutralizing Activity with Live Viruses
We determined the EC50 values for each mAb against represen-
tative infectious CHIKV strains of the East/Central/South African
(ECSA) genotype (LR2006 OPY1 [LR] strain), the West African
genotype (NI 64 IbH 35 strain), and the Asian genotype (RSU1
and 99659 [2014 Caribbean] strains) using a high-throughput
focus reduction neutralization test (FRNT) (Pal et al., 2013).
Twenty-five of the mAbs exhibited neutralizing activity against
at least one CHIKV strain (EC50 values < 10 mg/ml), with
8 mAbs exhibiting neutralization in a potent range (EC50 values
between 10 and 99 ng/ml), and 13mAbs exhibiting neutralization
in an ultrapotent range (Table 1). For comparative purposes, we
also tested the previously reported humanmAbs 5F10 and 8B10
against viruses of all three genotypes, and in every case the EC50
values were >100 ng/ml. In most cases, the mAbs we isolated
exhibited relatively similar neutralizing activity against virus
from all three genotypes. Six mAbs (2B4, 2H1, 4J21, 4N12,
5M16, and 9D14) inhibited viruses from all three genotypes
with ultrapotent activity. These data indicate that a single individ-
ual can develop multiple CHIKV-specific antibodies that are ul-
trapotent and broadly neutralizing.
Binding to E2 Protein
The CHIKV E2 protein is a dominant target of murine (Goh et al.,
2013; Lumet al., 2013), nonhumanprimate (Kamet al., 2014), andChuman (Fong et al., 2014; Kam et al., 2012a, 2012b; Selvarajah
et al., 2013) humoral responses. We tested the human mAbs for
binding to amonomeric form of the ectodomain of E2 protein ex-
pressed in E. coli (Pal et al., 2013). Nine mAbs bound strongly to
the E2 ectodomain, 6 exhibited moderate binding, 1 bound
weakly, and14 failed tobindabovebackground (Table 1). Theca-
pacity to bind purified E2 protein in vitro did not correlate directly
with neutralizing potency (Table 1). A subset of 17 human mAbs
was tested using a surface plasmon resonance assay for binding
to the p62-E1 protein derived from mammalian cells (Voss et al.,
2010). All mAbs bound in the nM range, with KD values from0.5 to
20 nM. Differences in binding kinetics did not correlate with anti-
genic specificity or functional activity (Table S1).
Competition-Binding Studies
To identify non-overlapping antigenic regions in recombinant
E2 protein recognized by different neutralizing mAbs, we used
a quantitative competition-binding assay. For comparison, we
also evaluated four previously described murine mAbs
(CHK-84, CHK-88, CHK-141, and CHK-265) (Pal et al., 2013)
and the previously described human mAb 5F10 (Warter et al.,
2011) (Figure S2). The pattern of competition was complex, but
three major competition groups were evident, which we desig-
nated group 1-3. We also defined a fourth group containing the
single human mAb, 5F19. These competition studies suggest
that there are at least three major antigenic regions recognized
by CHIKV-specific antibodies.
Epitope Mapping Using Alanine-Scanning Mutagenesis
We used an alanine-scanning mutagenesis library coupled with
cell-based expression and flow cytometry to identify residues
in E2 and E1 proteins of CHIKV strain S27 (ECSA genotype)
required for mAb binding (Fong et al., 2014) (Figure S3). Residues
required for mAb binding to CHIKV glycoproteins for a subset of
20 humanmAbs are listed in Table 1. Mutations affecting binding
of these 20 mAbs are indicated in an alignment of the full-length
E2 sequences of strain S27 and strains representing all CHIKV
genotypes that were used in our study (Figure 1A). The aa in
E2 that influence binding are located primarily in the solvent-
exposed regions of domains A and B and arches 1 and 2 of
the b-ribbon connector, which links domains A and B (Voss
et al., 2010) (Figure 1A). Comparison of the antigenic sites iden-
tified by loss-of-binding experiments using alanine-scanning
mutagenesis with the competition-binding analysis (Figure S2)
demonstrated that competition groups 1 and 2 generally corre-
sponded to sites within domain A and the arches, whereas group
3 corresponded to regions in domain B.
Structural Analysis of Antigenic Regions
A large and diverse number of the surface residues in domains A
and B and the arches are contacted by at least 1 of the mAbs
(Figures 1B and 1C). Two principal antigenic regions in E2 ac-
counted for the binding of multiple mAbs. The first region is
located in domain A, between residues 58 and 80, and contains
the putative receptor-binding domain (RBD) (Sun et al., 2014;
Voss et al., 2010). The second region is located in domain B, be-
tween residues 190 and 215. Both sequence regions project
away from the viral envelope and are located near the E2 trimer
apex (Figures S3 and S4).ell Host & Microbe 18, 86–95, July 8, 2015 ª2015 Elsevier Inc. 87
Table 1. Characteristics of Chikungunya Virus-Specific Human Monoclonal Antibodies
mAba
IgG
Sub-classb
l/k Light
Chainb
ELISA
Binding
to E2
Ectodomain
(10 mg/ml)c
Major Antigenic Site
Neutralization
against CHIKV
VRP (Strain
SL15649)f
EC50 in ng/ml
g
[95% Confidence
Interval]
In Vitro Neutralizing Potency and Breadth of CHIKV-Specific Human
mAbs
Competition
Binding Group
for Purified
E2 Proteind
Mutagenesis Mapping
Neutralization against CHIKV against Indicated Genotype and Strain*
EC50, ng/ml
g [95% Confidence Interval]
E2 Domaine
E2 Residues for which
Reduced Binding
Was Noted when
Altered to Alanine
West African
Genotype NI 64
IbH 35 Strain
ECSA Genotype
LR2006 OPY1
(LR) Strain
Asian Genotype
RSUI Strain
2014 Caribbean
99659 strain
2H1 IgG2 l ++ Low binding E2-DA R80, T116 8 [6–10] 3.7 (3.3–4.3) 5.6 (4.9–6.3) 5.9 (5.3–6.7) 5.5 (4.7–6.5)
4N12 IgG2 k  NT Arch D250 8 [7–10] 2.5 (2.0–3.1) 4.0 (3.3–5.0) 6.5 (5.7–7.3) 7.3 (5.9–9.2)
2B4 IgG1 l ++ Low binding NoReduct – 14 [11–17] 3.2 (2.8–3.7) 5.6 (4.6–6.7) 6.5 (5.6–7.7) 7.0 (6.0–8.2)
4J21 IgG1 l ++ Low binding NoReduct – 5 [4–6] 5.2 (4.3–6.4) 7.4 (6.6–8.3) 7.7 (7.0–8.6) 7.2 (5.3–9.8)
5M16 IgG1 k +++ 2 Arch G253 5 [4–6] 6. 0 (5.5–6.6) 5.9 (5.0–6.8) 8.4 (6.7–10.4) 11.7 (9.7–14.1)
9D14 IgG1 l +++ 2 NoReduct – 6 [5–7] 2.1 (1.6–2.7) 2.9 (2.3–3.7) 6.3 (4.7–8.4) 86.0 (31.5–235)
1H12 IgG1 l +++ 1/2 DA/B, Arch T58, D59, D60, R68,
D71, I74, D77, T191,
N193, K234
17 [14–20] 3.0 (2.5–3.5) 7.5 (6.7–8.4) 11.7 (9.3–14.8) 11.6 (8.2–16.2)
8E22 IgG1 l ++ Low binding DA, Arch H62, W64, R68, H99,
D117, I255
17 [14–19] 8.2 (7.0–9.7) 7.2 (6.4–8.3) 42.5 (30.8–58.5) 138.9 (64.7–298)
8G18 IgG1 l ++ Low binding DA H62, W64, D117 17 [14–19] 4.7 (4.1–5.3) 7.3 (6.3–8.4) 34.9 (24.9–48.9) 52.4 (24.1–114)
10N24 IgG1 k  NT DA,B W64, D71, R80, T116,
D117, I121, N187, I190
21 [17–26] 7.9 (6.9–9.0) 9.5 (8.2–11.0) 15.9 (13.2–19.2) 23.6 (18.3–30.5)
8I4 IgG1 k +++ NSF Ab DB, Arch M171, Q184, I190,
N193, V197, R198,
Y199, G209, L210,
K215, K234, V242, I255
8 [5–14] 6.9 (3.8–12.3) 6.2 (4.5–8.4) 153 (78–299) >
3N23 IgG1 k  NT DA, Arch D60, R68, G98, H170,
M171, K233, K234
25 [21–30] 6.0 (5.0–7.2) 10.1 (8.9–11.5) 14.1 (11.6–17.1) 8.7 (7.0–10.9)
5O14 IgG1 k +++ 2 NoReduct – 38 [30–47] 6.7 (5.5–8.3) 12.1 (10.9–13.5) 17.3 (14.2–21.1) 6.2 (5.3–7.2)
4J14 IgG1 l ++ Low binding DA/B D63, W64, T65, R80,
I121, A162, N193
23 [20–26] 12.9 (11.2–15.0) 17.7 (16.1–19.4) 23.1 (20–27) 23.0 (18.5–28.4)
3E23 IgG2 l  NT DA W64 11 [9–13] 19.4 (15.2–25.0) 18.7 (16.3–21.5) 36.0 (30.3–42.9) 38.0 (30.3–47.5)
1L1 IgG1 l +/ Low binding Arch G253 18 [15–22] 18.6 (15.5–22.4) 24.2 (21.3–27.5) 34.3 (29–40.7) ND
3B4 IgG3 k  NT DB V192, Q195 > 18.7 (10.7–32.8) 29.6 (18.7–46.8) 271 (144–511) ND
4B8 IgG1 l +++ 2 NoReduct – 0.6 [0.4–0.8] 22.8 (12.4–41.8) 28.1 (19.8–39.9) 234 (142–386) ND
4G20 IgG1 l  NT DB D174, R198, Y199,
K215
95 [60–160] 22.3 (17.3-29.0) 34.9 (28.2–43.8) 131.4 (88.5–195) ND
1O5 IgG1 l  NT DA W64, T65 138 [110–170] 30.1 (22.6–35.3) 37.6 (32.6–43.4) 48.9 (37.8–63.2) ND
1O6 IgG3 l  2 DA R80 5,200
[4,100–6,600]
61.7 (50.8–74.8) 57.5 (48.8–68.1) ND ND
(Continued on next page)
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Table 1. Continued
mAba
IgG
Sub-classb
l/k Light
Chainb
ELISA
Binding
to E2
Ectodomain
(10 mg/ml)c
Major Antigenic Site
Neutralization
against CHIKV
VRP (Strain
SL15649)f
EC50 in ng/ml
g
[95% Confidence
Interval]
In Vitro Neutralizing Potency and Breadth of CHIKV-Specific Human
mAbs
Competition
Binding Group
for Purified
E2 Proteind
Mutagenesis Mapping
Neutralization against CHIKV against Indicated Genotype and Strain*
EC50, ng/ml
g [95% Confidence Interval]
E2 Domaine
E2 Residues for which
Reduced Binding
Was Noted when
Altered to Alanine
West African
Genotype NI 64
IbH 35 Strain
ECSA Genotype
LR2006 OPY1
(LR) Strain
Asian Genotype
RSUI Strain
2014 Caribbean
99659 strain
2L5 NT NT  NT NoReduct – 4,600
[2,400–9,500]
1,076
(748–1,548)
2,361
(1,460–3,819)
5,632
(3,904–8,128)
ND
3A2 IgG1 k +++ 3 DB I190, R198, Y199,
G209, L210, T212
1,300
[830–1,900]
1,566
(1,111–2,207)
1,396 (952–2,046) > ND
5F19 IgG1 l +++ 4 DA H18 > > 9,064
(2,911–28,249)
> ND
1M9 IgG1 k  NT DA, Arch R36, H62, R80,
Q146, E165, E166,
N231, D250, H256
> > > 6,187
(2,795–13,709)
ND
1I9 IgG1 k  NT E2 – > > > > ND
4B10 IgG1 k  NT NoReduct – > > > > ND
2C2 IgG1 l  NT NoReduct – > > > > ND
2D12 IgG1 k  NT E2 – > > > > ND
5N23 IgG1 l +++ 1 DA, Arch E24, D117, I121 > > > > ND
murine
CHK-
152
IgG2c k  NT E2-DA,
E2-DB
D59, W235, A11,
M74, G194, N193,
T212, H232h
3 [2–4]
aOrder of antibodies reflects the level of potency degree and breadth of the antibodies in neutralization assays against clinical CHIKV isolates of diverse genotypes.
bImmunoglobulin isotype, subtype, and light chain use were determined by ELISA; NT indicates not tested due to poor growth of B cell line.
c() denotes no detectable binding [OD < 0.1]; (+/) denotes weak binding [OD 0.31–0.499]; (++) denotes moderate binding [OD 0.5–0.99]; (+++) denotes strong binding [OD > 1.0].
dValues shown represent combined data from two independent experiments; ‘‘Low binding’’ indicates incomplete mAb binding to E2 on biosensor for assessing competition; NT indicates not tested
since Ab did not bind E2 ectodomain in ELISA; ‘‘NSF Ab’’ indicates insufficient supply of mAb.
e‘‘-’’ indicates that the mAb did not react against the wild-type envelope proteins and could not be tested in this system; ‘‘NoReduct’’ indicates the mAb did bind to the wild-type E proteins, but no
reduction was noted reproducibly for any mutant; DA indicates domain A; DB indicates domain B; Arch indicates arch 1, arch 2, or both.
fValues shown represent combined data from two or more independent experiments.
gConcentration (ng/ml) at which 50% of virus was neutralized (EC50); (>) indicates EC50 value is greater than the highest mAb concentration tested (10 mg/ml); ND = Not Done.
hResidues identified by contacts with mAb in cryo-EM reconstruction (Sun et al., 2013).
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Positions at which alanine substitution disrupts binding for indicated mAb
Figure 1. Structural Analysis of E2 Residues Important for mAb Binding
(A) Sequence alignment of E2 from the CHIKV strains (indicated on the left) used in this study. The numbers above the sequence correspond to the aa position in
the mature E2 protein. Amino acids identical to strain S27 are indicated by a dash. Domains of E2 determined from the crystal structure of the E2/E1 heterodimer
(Voss et al., 2010) are depicted in the diagram above the alignment and are color coded (cyan, domain A; purple, b-ribbon connector; green, domain B; pink,
domain C; taupe shades, regions not present in the crystal structure). The position of residues at which alanine substitution disrupts mAb binding, as determined
(legend continued on next page)
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Mechanism of Neutralization
We conducted pre- and post-attachment neutralization assays
using mAbs displaying a range of inhibitory activities. As ex-
pected, all 5 mAbs tested neutralized infection efficiently when
pre-incubated with VRPs (Figure 2A). However, mAb 4B8 did
not neutralize VRPs completely even at high concentrations,
suggesting the presence of a fraction of CHIKV virions resistant
to this mAb; this pattern also was observed in assays using
viable CHIKV strains corresponding to the three distinct CHIKV
genotypes. In contrast, mAbs 3E23, 4J21, 5M16, and 9D14
completely neutralized infection when administered before
attachment. All five human mAbs also neutralized CHIKV infec-
tion when added following attachment, but we observed three
different patterns of activity (Figure 2A). mAb 4B8 was incapable
of complete neutralization when added post-attachment, and
the fraction of resistant virions was larger compared with that
observed following pre-attachment neutralization. mAb 9D14
neutralized VRPs with comparable efficiency whether added
before or after attachment. MAbs 3E23, 4J21, and 5M16 dis-
played complete neutralization of VRPs, but the efficiency of
neutralization post-attachment was lower than that following
pre-attachment. The mAbs 2H1 and 4N12 also efficiently
neutralized VRPs when added prior to or after attachment
(data not shown).
Fusion-from-without (FFWO) assay testing (Edwards and
Brown, 1986) of five of the ultrapotently neutralizing mAbs
(3E23, 4B8, 4J21, 5M16, or 9D14) revealed that all inhibited
fusion. In the absence of antibody treatment, a short pulse
of acidic pH-buffered medium resulted in infected cells, indi-
cating fusion between the viral envelope and plasma mem-
brane, whereas a pulse of neutral pH resulted in little to no
infection as expected (Figure 2B). Notably, all five human
mAbs inhibited plasma membrane fusion and infection, with
mAb 9D14 exhibiting the greatest potency in this assay. These
studies suggest that ultrapotently neutralizing mAbs block
CHIKV fusion.
mAb Prophylaxis In Vivo
We tested a subset of mAbs exhibiting diverse levels of neutral-
izing activity (Table 1) in a lethal infection model with 6-week-old,
highly immunodeficient Ifnar/ mice. Mice were pre-treated
with a single 50 mg dose (3 mg/kg) of human anti-CHIKV
mAbs or a West Nile virus (WNV)-specific isotype control
mAb (WNV hE16) 24 hr before subcutaneous injection with a le-
thal dose of CHIKV-LR2006. All mice treated with the isotype
control mAb succumbed to infection by 4 days post-inoculation.
Pretreatment with mAbs 4B8, 4J21, or 5M16 completely pro-
tected Ifnar/ mice, whereas treatment with mAbs 3E23 or
9D14 partially protected the infected animals, with 50% and
67% survival rates, respectively (Figure 3A). Surprisingly, mAb
2D12, which weakly neutralized in vitro, protected 80% of the
animals.by alanine-scanning mutagenesis, are designated by color-coded dots for each
indicated by squares shaded in gray, with the darker the shade of gray, the greate
(B) Location of residues required for mAb binding mapped onto the crystal structu
ribbon trace of a single heterodimer of E1/E2 is shown with E1 in light cyan and t
binding are shown as space-filling forms and color coded for each of the 20 indi
(C) A top view of the E1/E2 heterodimer, rotated 90 from the structure in (B). Als
CmAb Post-exposure Therapy In Vivo
Ifnar/ mice were inoculated with a lethal dose of CHIKV-
LR2006 and then administered a single 50 mg (3 mg/kg) dose
of representative mAbs 24 hr following virus inoculation. Thera-
peutic administration of mAb 4N12 or 5M16 mAbs provided
complete protection, whereas the isotype-control mAb provided
no protection, and others provided partial protection (Figure 3B).
To define further the therapeutic window of efficacy, Ifnar/
mice were administered a single 250 mg (14 mg/kg) dose of
representative mAbs 48 hr after challenge with CHIKV-LR2006.
Treatment with 4N12, 5M16, 4J21, and 4B8 protected 100%,
85%, 50%, and 12.5% of the animals, respectively (Figure 3C).
Remarkably, monotherapy with 4N12 or 4J21 at the later time
point of 60 hr protected 70% and 55% of animals when used
at a dose of 500 mg (28mg/kg) (Figure 3D). The observed differ-
ences in efficacy of the mAbs are likely not due to varying in vivo
half-life in mice, as there was no appreciable difference in the
rate of clearance in the serum for mAbs 4B8, 5M16, 4N12, and
4J21 (data not shown). These data establish that human mAbs
can protect against CHIKV-induced death, even at intervals
well after infection is established.
Combination mAb Therapy In Vivo
Given the possibility of resistance selection in vivo in animals
treated with a single anti-CHIKV mAb (Pal et al., 2013), we tested
whether a combination of two anti-CHIKV human mAbs could
protect mice against lethal challenge. We chose pairs of neutral-
izing mAbs based on the potency of individual mAbs in vitro as
well as protective activity in vivo as monotherapy. Ifnar/
mice were administered a single combination antibody treat-
ment dose of the most effective mAbs 60 hr after inoculation.
None of the combinations tested at varying doses ([4J21 +
2H1], [4J21 + 5M16], or [4J21 + 4N12]) provided superior protec-
tion to 4J21 or 4N12 monotherapy.
DISCUSSION
We report the isolation of a diverse panel of naturally occurring
human mAbs from a single individual, the majority of which
recognize the CHIKV E2 protein and display remarkable neutral-
izing activity in vitro and therapeutic efficacy in vivo. As a class,
the most inhibitory antibodies also exhibited broad activity,
neutralizing viruses from all three CHIKV genotypes, including
a strain currently circulating in the Caribbean. The majority of hu-
man CHIKV-specific mAbs isolated in this study neutralized the
virus at concentrations <100 ng/ml, and many exhibited inhibi-
tory activity at <10 ng/ml. This activity is greater than we have
observed in our previous studies of human mAbs against other
pathogenic human viruses, including H1, H2, H3, or H5 influenza
viruses (Hong et al., 2013; Krause et al., 2010, 2011a, 2011b,
2012; Thornburg et al., 2013; Yu et al., 2008), dengue viruses
(Messer et al., 2014; Smith et al., 2012, 2013a, 2013b, 2014),specific mAb. Residues that influence the binding of multiple antibodies are
r number of antibodies influenced by substitution at that residue (legend in B).
re of the mature envelope glycoprotein complex (PDB ID 3N41). A side view of a
he domains of E2 colored as in (A). The side chains of the aa required for mAb
vidual antibodies according to the legend in (A).
o see Figures S3 and S4.
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Figure 2. Mechanism of Neutralization by Human Anti-CHIKV mAbs
(A) Pre- and post-attachment neutralization assays. SL15649 VRPs were (1)
incubatedwith themAbsshown (includingCHK-152,apositivecontrolmAb)prior
toaddition topre-chilledVerocells, followedby removalofunboundvirusby three
washes (pre-attachment; filled circle) or (2) allowed to adsorb to pre-chilled Vero
cells followed by addition of the indicatedmAbs (post-attachment; open circles).
(B) FFWO assay. SL15649 VRPs were adsorbed to pre-chilled Vero cells,
followed by addition of themAbs shown (including CHK-152, a positive control
murine mAb). Unbound virus was removed, and cells were exposed to low (pH
5.5 to trigger viral fusion at the plasma membrane; filled circles) or neutral (pH
7.4 as a control; open circles) pH medium at 37C for 2 min. For both (A) and
(B), cells were incubated at 37C until 18 hr after infection, and GFP-positive
cells were quantified using fluorescence microscopy. The data are combined
from two independent experiments, each performed in triplicate, and repre-
sented as mean ± SEM.
92 Cell Host & Microbe 18, 86–95, July 8, 2015 ª2015 Elsevier Inc.and others. The potency of many human CHIKVmAbs is compa-
rable to or exceeds that of best-in-class murine neutralizing
CHIKV mAbs (Fric et al., 2013; Pal et al., 2013; Warter et al.,
2011), which were generated after iterative boosting and affinity
maturation. Most other neutralizing human mAbs against CHIKV
are substantially less potent (Fong et al., 2014; Selvarajah et al.,
2013; Warter et al., 2011). A single previously reported human
CHIKV-specific mAb (IM-CKV063) displays activity comparable
to the ultrapotent neutralizing mAbs reported here (Fong et al.,
2014).
We observed a diversity of epitope recognition patterns in E2
by the different neutralizing CHIKV mAbs tested. Fine epitope
mapping with alanine-substituted CHIKV glycoproteins showed
that recognition of three structural regions in E2 is associated
with mAb-mediated neutralization: domain A, which contains
the putative RBD (Sun et al., 2013; Voss et al., 2010), domain
B, which contacts and shields the fusion loop in E1 (Voss
et al., 2010), and arches 1 and 2 of the b-ribbon connector, which
contains an acid-sensitive region and links domains A and B
(Voss et al., 2010). Of the antibodies mapped to epitopes in
E2, the bulk (those in competition groups 1 and 2) preferentially
recognized sites in domain A and arches 1 and 2, whereas a
smaller group (in competition group 3) recognized sites in
domain B. These data suggest that surface-exposed regions in
domain A and the arches are dominant antigenic sites that elicit
human neutralizing antibody responses. We conclude that the
highly conserved region in domain A and arch 2 might elicit a
broadly protective immune response and serve as an attractive
candidate for epitope-focused vaccine design.
Remarkably, almost a quarter of surface-exposed residues in
the critical E2 domains appear to be engaged by one or more
mAbs from a single individual. The existence of functionally
diverse binding modes on the major antigenic sites is implied
by two observations: (1) some mAbs bound to similar epitopes
but exhibited inhibitory activity that varied by several orders of
magnitude and (2) there was little correlation between neutraliza-
tion capacity and affinity of binding to E2 protein. Seven of the
most potently neutralizing human mAbs (2H1, 3E23, 4B8,
4J21, 4N12, 5M16, and 9D14) inhibited CHIKV infection at a
step following attachment, likely via prevention of pH-dependent
structural changes, which prevents nucleocapsid penetration
into the cytoplasm (Kielian et al., 2010).
As therapeutic efficacy in mice appears to predict treatment
outcomes in experimentally induced infection and arthritis in
nonhuman primates (Pal et al., 2013, 2014), the data here sug-
gest that prophylaxis of humans with CHIKV-specific human
mAbs would prevent infection. Given concerns about selection
of resistant variants with monotherapy (Pal et al., 2013), combi-
nation therapy using ultrapotent neutralizing antibodies that
target different regions of E2 may be desirable. Unexpectedly,
we did not observe a superior therapeutic effect for combina-
tions of mAbs compared with monotherapy at late time points
in these studies with immunodeficient mice. In fact, the survival
in most groups treated with combination therapy trended toward
less protection than that of the groups treated with 4J21 or 4N12
alone. Although further study is warranted, the lack of enhanced
therapeutic benefit with the particular mAb combinations tested
could be due to competition or structural hindrance of binding of
individual antibody molecules to adjacent epitopes on E2
Figure 3. Human mAb Prophylaxis and Therapy against Lethal CHIKV Infection in Ifnar–/– Mice
(A–C) Mice were administered either 50 or 250 mg of indicated CHIKV-specific or control mAb by intraperitoneal injection 24 hr before (A; n = 6 to 8 mice per mAb
tested) or 24 hr (B; n = 5 to 8 mice per mAb tested) or 48 hr after (C); n = 7 to 10 mice per mAb tested) a lethal challenge of CHIKV.
(D) Mice were administered 150, 250, or 500 mg of indicated CHIKV-specific mAbs in combination by intraperitoneal injection 60 hr after a lethal challenge of
CHIKV (n = 6 to 13 mice per mAb combination tested). For monotherapy with 4J21, 4N12, or hE16 (negative control), a single dose of 500 mg was given (n = 10 to
17mice per mAb tested). All data in this figure were pooled from at least two independent experiments. The following statistical analysis was performed using the
Mantel-Cox log rank test: 4N12 versus 4J21, p = 0.39; 4N12 (500 mg) versus 4N12 (250 mg) + 4J21 (250 mg), p = 0.69; 4N12 (500 mg) versus 4N12 (500 mg) + 4J21
(150 mg), p = 0.13; 4N12 (500 mg) versus 4N12 (500 mg) + 4J21 (500 mg), p = 0.06. All Ab administrations with the exception of 4J21 (250 mg) + 2H1 (250 mg) differed
significantly from the hE16 control (p < 0.002).proteins on the icosahedral virion surface. In comparison, a prior
study with anti-E2 (CHK-152) and anti-E1 (CHK-166) mouse
MAbs did show advantage as combination therapy (Pal et al.,
2013). Regardless, our data suggest that patient populations at
markedly increased risk of severe disease could be targeted
for prophylaxis or treatment with human anti-CHIKV mAbs dur-
ing outbreaks, including those with serious underlying medical
conditions (e.g., late-term pregnant women, the immunocom-
promised, and the elderly). Further clinical testing is planned to
determine whether neutralizing human mAbs can prevent or
ameliorate established joint disease in humans.
EXPERIMENTAL PROCEDURES
Isolation of Human mAbs
PBMCs were obtained from a human 5.5 years after documented symptom-
atic CHIKV infection in Sri Lanka. B cells were transformed with EBV in the
presence of CpG. The supernatants from the resulting B cell lymphoblastic
cells lines were screened for CHIKV-neutralizing activity using SL15649
VRPS. Positive wells were further selected for the presence of human
CHIKV-specific binding antibodies by ELISA using live CHIKV vaccine strain
181/25 virus as antigen. Transformed B cells were collected and fused to a
myeloma cell line, distributed into culture plates and expansion, and selected
by growth in hypoxanthine-aminopterin-thymidine medium containing
ouabain. Hybridomas were cloned by single-cell sorting. Supernatants from
cloned hybridomas growing in serum-free medium were collected, purified,
and concentrated from clarified medium by protein G chromatography.
Neutralization Assays
Purified IgG mAb proteins were tested for neutralizing activity using CHIKV
VRPs or fully infectious CHIKV. VRPs were incubated with serial dilutions of
mAbs then inoculated onto Vero 81 cell monolayers for 18 hr; infected cells
and total cells (identified with a nuclear marker) were identified with a fluores-
cence imaging system. Neutralizing activity for four infectious virus strains wasCdetermined in a focus reduction neutralization test (Pal et al., 2013). Serial di-
lutions of mAbs were incubated with 100 focus-forming units of CHIKV and
then added to Vero cells. Foci were detected with a mouse anti-CHIKV mAb
after cell fixation using immunoperoxidase detection and quantified using an
ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies).
E2 ELISA
Recombinant CHIKV E2 ectodomain protein (corresponding to the CHIKV-
LR2006 strain) was generated in E. coli (Pal et al., 2013) and adsorbed to
microtiter plates. Human mAbs were applied, and bound CHIKV-specific
mAbs were detected with biotin-conjugated goat anti-human IgG.
Competition Binding Assay
We identified groups of antibodies binding to the same major antigenic site by
competing pairs of antibodies for binding to CHIKV-LR2006 E2 ectodomain
protein containing a polyhistidine-tag attached to an Anti-Penta-His biosensor
tip (ForteBio 18-5077) in an Octet Red biosensor (ForteBio).
Alanine Scanning Mutagenesis for Epitope Mapping
ACHIKV envelope protein expression construct (strain S27, Uniprot Reference
Q8JUX5) with a C-terminal V5 tag was subjected to alanine-scanning muta-
genesis to generate a comprehensive mutation library. Primers were designed
to mutate each residue within the E2, 6K, and E1 regions of the envelope pro-
teins (residues Y326 to H1248 in the structural polyprotein) to alanine; alanine
codons were mutated to serine. In total, 910 CHIKV envelope protein mutants
were generated. Loss of binding of mAbs to each construct was determined
using an immunofluorescence binding assay, using cellular fluorescence de-
tected with a high-throughput flow cytometer.
Mechanism of Neutralization
MAbs were interacted with VRPs before or after attachment to Vero 81 cells,
and then cells were stained, imaged, and analyzed as described for VRP
neutralization assays to determine at what stage mAbs exerted the antiviral ef-
fect. Fusion-from-without assays were performed as detailed in Supplemental
Experimental Procedures.ell Host & Microbe 18, 86–95, July 8, 2015 ª2015 Elsevier Inc. 93
In Vivo Protection Studies in Mice
Ifnar/ mice were bred in pathogen-free animal facilities and infection
experiments were performed in A-BSL3 facilities. Footpad injections were
performed under anesthesia. For prophylaxis studies, human mAbs were
administered by intraperitoneal injection to 6-week-old Ifnar/ mice 1 day
prior to subcutaneous inoculation in the footpad with 10 FFU of CHIKV-LR.
For therapeutic studies, 10 FFU of CHIKV-LR was delivered 24, 48, or 60 hr
prior to administration of a single dose of individual or combinations of human
mAbs at specified doses.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2015.06.009.
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